H1-antihistamines for the treatment of anaphylaxis with and without shock
Country of origin: USA
Click for Full Details: www.mrw.interscience.wiley.comAnaphylaxis is a rare, but potentially life-threatening emergency. Evidence suggests that incidence may be increasing rapidly. Common triggers of anaphylaxis include a variety of foods, drugs and insect venoms.
H1-antihistamines are commonly used for the emergency treatment of anaphylaxis although the evidence underpinning this treatment is unclear. A systematic review of the literature has been conducted, searching key databases for high quality published and unpublished material on this subject; in addition, experts in this area and relevant pharmaceutical companies were contacted.
The searches failed to retrieve any randomised controlled trials on this subject. The review concludes there is no evidence from randomised controlled trials to support the use of H1-antihistamines in the emergency management of anaphylaxis.
The Cochrane review is available online.
Click for Full Details: www.mrw.interscience.wiley.com
Clinical Pain Advisor. December 2018
Managing Head Injury. December 2018
OrthoFlow pocket orthopaedic specialist. December 2018
The CDC Clear Communication Index November 2018
Prevention of HAI Observation Tools November 2018
Visual communication can benefit all audiences November 2018
Emergency Preparedness, Resilience and Response (EPRR) November 2018
Emergency Department design toolkit October 2018
Research on treating bacterial meningitis October 2018
WISER application for first responders October 2018